Joanne LaFleur, PharmD, MSPH

Although the demand for generic competition in the biopharmaceutical market could potentially be great, regulators have been slow to clear a pathway for the approval of generic biopharmaceuticals.

As we hear about the many wonders of statin therapy-most recently blood pressure reduction-it recalls the past 30 years of debate about the benefits of daily aspirin.

Hyperlipidemia is one of the most treatable causes of coronary artery disease. This toolkit for pharmacists will help patients design a cholesterol-lowering program, armed with the right medications and the right information.

A glossary explaining some common biotechnology and biopharmaceutical

Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.

Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.

Dr. LaFleur is a research assistant professor in the University of Utah College of Pharmacy Pharmacotherapy Outcomes Research Center within the Department of Pharmacotherapy.